428 related articles for article (PubMed ID: 33691794)
1. Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells.
Dominici C; Sgarioto N; Yu Z; Sesma-Sanz L; Masson JY; Richard S; Raynal NJ
Clin Epigenetics; 2021 Mar; 13(1):54. PubMed ID: 33691794
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Fedoriw A; Rajapurkar SR; O'Brien S; Gerhart SV; Mitchell LH; Adams ND; Rioux N; Lingaraj T; Ribich SA; Pappalardi MB; Shah N; Laraio J; Liu Y; Butticello M; Carpenter CL; Creasy C; Korenchuk S; McCabe MT; McHugh CF; Nagarajan R; Wagner C; Zappacosta F; Annan R; Concha NO; Thomas RA; Hart TK; Smith JJ; Copeland RA; Moyer MP; Campbell J; Stickland K; Mills J; Jacques-O'Hagan S; Allain C; Johnston D; Raimondi A; Porter Scott M; Waters N; Swinger K; Boriack-Sjodin A; Riera T; Shapiro G; Chesworth R; Prinjha RK; Kruger RG; Barbash O; Mohammad HP
Cancer Cell; 2019 Jul; 36(1):100-114.e25. PubMed ID: 31257072
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition.
Bedard GT; Gilaj N; Peregrina K; Brew I; Tosti E; Shaffer K; Tyler PC; Edelmann W; Augenlicht LH; Schramm VL
J Biol Chem; 2024 Jan; 300(1):105492. PubMed ID: 38000655
[TBL] [Abstract][Full Text] [Related]
4. A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases.
Eram MS; Shen Y; Szewczyk M; Wu H; Senisterra G; Li F; Butler KV; Kaniskan HÜ; Speed BA; Dela Seña C; Dong A; Zeng H; Schapira M; Brown PJ; Arrowsmith CH; Barsyte-Lovejoy D; Liu J; Vedadi M; Jin J
ACS Chem Biol; 2016 Mar; 11(3):772-781. PubMed ID: 26598975
[TBL] [Abstract][Full Text] [Related]
5. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
Kryukov GV; Wilson FH; Ruth JR; Paulk J; Tsherniak A; Marlow SE; Vazquez F; Weir BA; Fitzgerald ME; Tanaka M; Bielski CM; Scott JM; Dennis C; Cowley GS; Boehm JS; Root DE; Golub TR; Clish CB; Bradner JE; Hahn WC; Garraway LA
Science; 2016 Mar; 351(6278):1214-8. PubMed ID: 26912360
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.
Michels J; Vitale I; Senovilla L; Enot DP; Garcia P; Lissa D; Olaussen KA; Brenner C; Soria JC; Castedo M; Kroemer G
Cell Cycle; 2013 Mar; 12(6):877-83. PubMed ID: 23428903
[TBL] [Abstract][Full Text] [Related]
7. Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance.
Zhu Y; Xia T; Chen DQ; Xiong X; Shi L; Zuo Y; Xiao H; Liu L
Drug Resist Updat; 2024 Jan; 72():101016. PubMed ID: 37980859
[TBL] [Abstract][Full Text] [Related]
8. PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition.
Li Y; Dobrolecki LE; Sallas C; Zhang X; Kerr TD; Bisht D; Wang Y; Awasthi S; Kaundal B; Wu S; Peng W; Mendillo ML; Lu Y; Jeter CR; Peng G; Liu J; Westin SN; Sood AK; Lewis MT; Das J; Yi SS; Bedford MT; McGrail DJ; Sahni N
Cell Rep Med; 2023 Dec; 4(12):101326. PubMed ID: 38118413
[TBL] [Abstract][Full Text] [Related]
9. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells.
Hori H; Tran P; Carrera CJ; Hori Y; Rosenbach MD; Carson DA; Nobori T
Cancer Res; 1996 Dec; 56(24):5653-8. PubMed ID: 8971171
[TBL] [Abstract][Full Text] [Related]
10. MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
Kalev P; Hyer ML; Gross S; Konteatis Z; Chen CC; Fletcher M; Lein M; Aguado-Fraile E; Frank V; Barnett A; Mandley E; Goldford J; Chen Y; Sellers K; Hayes S; Lizotte K; Quang P; Tuncay Y; Clasquin M; Peters R; Weier J; Simone E; Murtie J; Liu W; Nagaraja R; Dang L; Sui Z; Biller SA; Travins J; Marks KM; Marjon K
Cancer Cell; 2021 Feb; 39(2):209-224.e11. PubMed ID: 33450196
[TBL] [Abstract][Full Text] [Related]
11. A patent review of arginine methyltransferase inhibitors (2010-2018).
Li X; Wang C; Jiang H; Luo C
Expert Opin Ther Pat; 2019 Feb; 29(2):97-114. PubMed ID: 30640571
[TBL] [Abstract][Full Text] [Related]
12. BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells.
Fiorentino FP; Marchesi I; Schröder C; Schmidt R; Yokota J; Bagella L
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33339368
[TBL] [Abstract][Full Text] [Related]
13. The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity.
Xuan YF; Lu S; Ou YJ; Bao XB; Huan XJ; Song SS; Miao ZH; Wang YQ
Biochem Biophys Res Commun; 2024 Jul; 716():150011. PubMed ID: 38704890
[TBL] [Abstract][Full Text] [Related]
14. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
15. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
[TBL] [Abstract][Full Text] [Related]
16. Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells.
Ryu H; Choi HK; Kim HJ; Kim AY; Song JY; Hwang SG; Kim JS; Kim DU; Kim EH; Kim J; Ahn J
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554189
[TBL] [Abstract][Full Text] [Related]
17. MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients.
Su CY; Chang YC; Chan YC; Lin TC; Huang MS; Yang CJ; Hsiao M
Eur J Surg Oncol; 2014 Sep; 40(9):1143-50. PubMed ID: 24969958
[TBL] [Abstract][Full Text] [Related]
18. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment.
Zhang Y; Xu M; Yuan J; Hu Z; Jiang J; Huang J; Wang B; Shen J; Long M; Fan Y; Montone KT; Tanyi JL; Tavana O; Chan HM; Hu X; Zhang L
bioRxiv; 2024 May; ():. PubMed ID: 38826355
[TBL] [Abstract][Full Text] [Related]
19. Small Molecule Inhibitors of Protein Arginine Methyltransferases.
Hu H; Qian K; Ho MC; Zheng YG
Expert Opin Investig Drugs; 2016; 25(3):335-58. PubMed ID: 26789238
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
Paul I; Savage KI; Blayney JK; Lamers E; Gately K; Kerr K; Sheaff M; Arthur K; Richard DJ; Hamilton PW; James JA; O'Byrne KJ; Harkin DP; Quinn JE; Fennell DA
J Pathol; 2011 Aug; 224(4):564-74. PubMed ID: 21706479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
